TY - JOUR
T1 - Clinical epigenetics settings for cancer and cardiovascular diseases
T2 - real-life applications of network medicine at the bedside
AU - on behalf of the International Network Medicine Consortium
AU - Sarno, Federica
AU - Benincasa, Giuditta
AU - List, Markus
AU - Barabasi, Albert Lazlo
AU - Baumbach, Jan
AU - Ciardiello, Fortunato
AU - Filetti, Sebastiano
AU - Glass, Kimberly
AU - Loscalzo, Joseph
AU - Marchese, Cinzia
AU - Maron, Bradley A.
AU - Paci, Paola
AU - Parini, Paolo
AU - Petrillo, Enrico
AU - Silverman, Edwin K.
AU - Verrienti, Antonella
AU - Altucci, Lucia
AU - Napoli, Claudio
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Despite impressive efforts invested in epigenetic research in the last 50 years, clinical applications are still lacking. Only a few university hospital centers currently use epigenetic biomarkers at the bedside. Moreover, the overall concept of precision medicine is not widely recognized in routine medical practice and the reductionist approach remains predominant in treating patients affected by major diseases such as cancer and cardiovascular diseases. By its’ very nature, epigenetics is integrative of genetic networks. The study of epigenetic biomarkers has led to the identification of numerous drugs with an increasingly significant role in clinical therapy especially of cancer patients. Here, we provide an overview of clinical epigenetics within the context of network analysis. We illustrate achievements to date and discuss how we can move from traditional medicine into the era of network medicine (NM), where pathway-informed molecular diagnostics will allow treatment selection following the paradigm of precision medicine.
AB - Despite impressive efforts invested in epigenetic research in the last 50 years, clinical applications are still lacking. Only a few university hospital centers currently use epigenetic biomarkers at the bedside. Moreover, the overall concept of precision medicine is not widely recognized in routine medical practice and the reductionist approach remains predominant in treating patients affected by major diseases such as cancer and cardiovascular diseases. By its’ very nature, epigenetics is integrative of genetic networks. The study of epigenetic biomarkers has led to the identification of numerous drugs with an increasingly significant role in clinical therapy especially of cancer patients. Here, we provide an overview of clinical epigenetics within the context of network analysis. We illustrate achievements to date and discuss how we can move from traditional medicine into the era of network medicine (NM), where pathway-informed molecular diagnostics will allow treatment selection following the paradigm of precision medicine.
KW - Algorithms
KW - CVD
KW - Cancer
KW - Epi-drugs
KW - Epigenetics
KW - Network medicine
KW - Precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85103380934&partnerID=8YFLogxK
U2 - 10.1186/s13148-021-01047-z
DO - 10.1186/s13148-021-01047-z
M3 - Review Article
C2 - 33785068
AN - SCOPUS:85103380934
SN - 1868-7075
VL - 13
JO - Clinical Epigenetics
JF - Clinical Epigenetics
IS - 1
M1 - 66
ER -